PARs drug reduces cartilage degradation in subjects with OA
Filed with ASX · · 5 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm files first IND with US FDA
- Appendix 4C - quarterly
- Paradigm EOFY Update
- PAR reports successful Ross River phase 2 clinical trial
- PAR reports consistent pain reduction in knee OA of patients
Later from Paradigm Biopharmaceuticals
- Appendix 4E and 2019 Annual Report
- PAR Expanded Access IND Cleared by US FDA
- Osteoarthritis pain reduced by Paradigms Zilosul (PPS)
- Paradigm provides regulatory filing update
- Paradigm AGM Presentation
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals